How would your patients advise themselves to treat their next HAE attack?
Even with prophylactic treatment, people living with HAE continue to experience attacks and face complex on-demand treatment decisions that lead to delays in treatment. 1-3
Read Patient Letters
alt="bg">
How would your patients advise themselves to treat their next HAE attack?
Even with prophylactic treatment, people living with HAE continue to experience attacks and face complex on-demand treatment decisions that lead to delays in treatment. 1-3
Read Patient Letters-
EVEN PATIENTS ON
PROPHYLAXIS CONTINUE
TO HAVE ATTACKS,
CAUSING THEM TO
MODIFY THEIR LIVES1,2Learn how attacks continue to
View HAE Attack Management
impact quality of life for HAE
patients, even with treatment
advances, like prophylaxis.1,2 -
ARE YOUR PATIENTS MISSING THE OPPORTUNITY
TO TREAT ATTACKS EARLY?The HAE Attack Journey Survey has revealed that patients face challenges in treating HAE attacks, leading to prolonged attacks and significant burden.1,3,4
LEARN MORE
Real Stories
of Attack Burden
Join Dr. Burnette and patients living
with HAE
as they discuss the persistent
burden of HAE
and the variety
of reasons patients delay
or
avoid treatment.
Receive HAE updates, including real-world patient experiences and access to
resources created for healthcare professionals, by healthcare professionals.
References: 1. Betschel S, van Kooten S, Heckmann M, Danese S, Goga L, Guilarte M. Remaining burden of hereditary angioedema (HAE) attacks despite modern long-term prophylaxis. Abstract presented at: EAACI 2023 Hybrid Congress, June 9-11, 2023; Hamburg, Germany. Allergy. In Press. 2. Betschel S, van Kooten S, Heckmann M, Danese S, Goga L, Guilarte M. HAE patients decision to carry on-demand treatment when away from home. Abstract presented at: 13th C1-inhibitor Deficiency & Angioedema Workshop, May 4-7, 2023; Budapest, Hungary. Allergy Asthma Clin Immunol. In Press. 3. Grumach A, van Kooten S, Heckmann M, Danese S, Goga L, Garcez T. Understanding the complex decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks. Abstract presented at: EAACI 2023 Hybrid Congress, June 9-11, 2023; Hamburg, Germany. Allergy. In Press. 4. Maurer M, Aberer W, Caballero T, et al. The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema. Clin Exp Allergy. 2022;52:1048-1058. doi:10.1111/cea.14206 5. Soteres D, Grumach A, van Kooten A, Malloy N, Heckmann M, Ulloa J, Burnette A. Anxiety associated with refilling on-demand therapy for HAE attacks contributes to treatment delay and non-treatment. Abstract presented at: AAAAI 2024 Annual Meeting, February 23-26, 2024; Washington, DC. J Allergy Clin Immunol. In Press.
Back to top